Diuretics in the Management of Cardiorenal Syndrome

Adv Chronic Kidney Dis. 2018 Sep;25(5):425-433. doi: 10.1053/j.ackd.2018.08.008.

Abstract

The leading cause of death worldwide is cardiovascular disease. The heart and the kidneys are functionally interdependent, such that dysfunction in one organ may cause dysfunction in the other. By one estimate, more than 60% of patients with congestive heart failure develop chronic kidney disease. Volume overload and congestion are hallmarks of heart failure, and these findings are associated with severe symptoms and poor outcomes. Given the importance of congestion, diuretics remain a cornerstone of heart failure management. However, diuretic treatment remains largely empirical, with little evidence currently available to guide decisions. In this review, we discuss the pathophysiology of cardiorenal syndrome, the pharmacology of loop diuretics, mechanisms of diuretic resistance, and evidence-based treatment paradigms.

Keywords: Cardiorenal syndrome; Chronic kidney disease; Congestive heart failure; Diuretic resistance; Diuretics.

Publication types

  • Review

MeSH terms

  • Acute Kidney Injury / drug therapy
  • Acute Kidney Injury / prevention & control
  • Cardio-Renal Syndrome / classification
  • Cardio-Renal Syndrome / drug therapy*
  • Cardio-Renal Syndrome / mortality
  • Cardio-Renal Syndrome / physiopathology
  • Disease Progression*
  • Heart Failure / drug therapy
  • Heart Failure / prevention & control
  • Humans
  • Male
  • Prognosis
  • Risk Assessment
  • Severity of Illness Index
  • Sodium Potassium Chloride Symporter Inhibitors / therapeutic use*
  • Survival Analysis
  • Treatment Outcome

Substances

  • Sodium Potassium Chloride Symporter Inhibitors